Peter H. Silverstone

1.2k total citations
30 papers, 912 citations indexed

About

Peter H. Silverstone is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Peter H. Silverstone has authored 30 papers receiving a total of 912 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Psychiatry and Mental health, 9 papers in Cellular and Molecular Neuroscience and 8 papers in Molecular Biology. Recurrent topics in Peter H. Silverstone's work include Bipolar Disorder and Treatment (8 papers), Pain Mechanisms and Treatments (5 papers) and Neuroscience and Neuropharmacology Research (5 papers). Peter H. Silverstone is often cited by papers focused on Bipolar Disorder and Treatment (8 papers), Pain Mechanisms and Treatments (5 papers) and Neuroscience and Neuropharmacology Research (5 papers). Peter H. Silverstone collaborates with scholars based in Canada, United Kingdom and United States. Peter H. Silverstone's co-authors include Arun Ravindran, Andrew J. Greenshaw, Philip J. Cowen, Hyeon-Jin Kim, Brent M McGrath, Susan Rotzinger, Christopher C. Hanstock, Trevor Sharp, Brendan M. Johnson and Turlough O’Donnell and has published in prestigious journals such as The Lancet, Biological Psychiatry and Psychopharmacology.

In The Last Decade

Peter H. Silverstone

29 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter H. Silverstone Canada 18 348 281 223 182 134 30 912
AF Cohen Netherlands 17 253 0.7× 373 1.3× 294 1.3× 170 0.9× 97 0.7× 31 1.0k
Kristin L. Bigos United States 15 356 1.0× 177 0.6× 256 1.1× 231 1.3× 104 0.8× 26 1.1k
Burton J. Goldstein United States 14 233 0.7× 198 0.7× 242 1.1× 112 0.6× 176 1.3× 47 755
C. Barnas Austria 19 700 2.0× 166 0.6× 197 0.9× 111 0.6× 61 0.5× 61 1.2k
Ádám Nagy Hungary 14 350 1.0× 187 0.7× 495 2.2× 86 0.5× 229 1.7× 40 1.1k
A Puech France 15 289 0.8× 359 1.3× 160 0.7× 258 1.4× 76 0.6× 46 1.0k
P. J. Perry United States 12 526 1.5× 138 0.5× 216 1.0× 101 0.6× 97 0.7× 20 872
Meghan M. Grady United States 9 334 1.0× 137 0.5× 317 1.4× 83 0.5× 124 0.9× 16 808
James F. Pradko United States 6 540 1.6× 157 0.6× 389 1.7× 150 0.8× 146 1.1× 6 1.2k
Alexander Nies United States 14 228 0.7× 218 0.8× 156 0.7× 98 0.5× 69 0.5× 23 739

Countries citing papers authored by Peter H. Silverstone

Since Specialization
Citations

This map shows the geographic impact of Peter H. Silverstone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter H. Silverstone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter H. Silverstone more than expected).

Fields of papers citing papers by Peter H. Silverstone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter H. Silverstone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter H. Silverstone. The network helps show where Peter H. Silverstone may publish in the future.

Co-authorship network of co-authors of Peter H. Silverstone

This figure shows the co-authorship network connecting the top 25 collaborators of Peter H. Silverstone. A scholar is included among the top collaborators of Peter H. Silverstone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter H. Silverstone. Peter H. Silverstone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shalaby, Reham, Belinda Agyapong, Ejemai Eboreime, et al.. (2025). Predictors of poor quality of life for patients discharged from acute psychiatric care in Alberta. Frontiers in Psychiatry. 16. 1619292–1619292.
2.
Silverstone, Peter H., et al.. (2008). Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice. Annals of General Psychiatry. 7(1). 27–27. 4 indexed citations
3.
Silverstone, Peter H., et al.. (2008). Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice. Annals of General Psychiatry. 7(1). 19–19. 25 indexed citations
4.
Silverstone, Peter H., et al.. (2008). Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride. Annals of General Psychiatry. 7(1). 11–11. 12 indexed citations
5.
Silverstone, Peter H., et al.. (2007). Single- and multiple-dose bioequivalence of two once-daily tramadol formulations using stereospecific analysis of tramadol and its demethylated (M1 and M5) metabolites. Current Medical Research and Opinion. 23(7). 1593–1604. 7 indexed citations
6.
Silverstone, Peter H., Brent M McGrath, & Hyeon-Jin Kim. (2005). Bipolar disorder and myo‐inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disorders. 7(1). 1–10. 98 indexed citations
7.
Wu, Ren & Peter H. Silverstone. (2001). No significant change of brain myo-inositol is observed in bipolar affective disorder after sodium valproate medication by in vivo proton MR spectroscopy. 3 indexed citations
8.
Silverstone, Peter H., et al.. (1999). Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by 1H and 31P MRS. Biological Psychiatry. 46(12). 1634–1641. 24 indexed citations
9.
Silverstone, Peter H., et al.. (1999). Once-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and Anxiety. The Journal of Clinical Psychiatry. 60(1). 22–28. 208 indexed citations
10.
Silverstone, Peter H., et al.. (1998). Lithium does not attenuate the effects of d-amphetamine in healthy volunteers. Psychiatry Research. 79(3). 219–226. 27 indexed citations
11.
Silverstone, Peter H., et al.. (1997). Diltiazem, a calcium antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteers. International Clinical Psychopharmacology. 12(2). 113–120. 13 indexed citations
12.
Greenshaw, Andrew J. & Peter H. Silverstone. (1997). The Non-Antiemetic Uses of Serotonin 5-HT3 Receptor Antagonists. Drugs. 53(1). 20–39. 83 indexed citations
13.
Silverstone, Peter H., et al.. (1994). The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. International Clinical Psychopharmacology. 9(3). 173–178. 36 indexed citations
14.
Silverstone, Peter H. & Philip J. Cowen. (1994). The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biological Psychiatry. 36(5). 309–316. 26 indexed citations
15.
Silverstone, Peter H., et al.. (1993). In vivo monoamine release during naloxane-precipitated morphine withdrawal. Neuroreport. 4(8). 1043–1045. 17 indexed citations
16.
17.
Silverstone, Peter H., Bankole A. Johnson, & Philip J. Cowen. (1992). Does ondansetron attenuate amphetamine-induced behaviour in human volunteers?. Psychopharmacology. 107(1). 140–141. 20 indexed citations
18.
Silverstone, Peter H., et al.. (1992). Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine. International Clinical Psychopharmacology. 7(1). 37–44. 37 indexed citations
19.
Silverstone, Peter H., et al.. (1992). The calcium channel antagonist nifedipine causes confusion when used to treat opiate withdrawal in morphine-dependent patients. International Clinical Psychopharmacology. 7(2). 87–90. 2 indexed citations
20.
Silverstone, Peter H. & David G. Grahame‐Smith. (1991). Effects of chronic lithium, amitriptyline, and electroconvulsive shock, on calcium channel binding in a rat brain homogenate. Psychopharmacology. 105(1). 132–133. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by AF Cohen Breakdown of academic impact, for papers by Kristin L. Bigos Breakdown of academic impact, for papers by Burton J. Goldstein Breakdown of academic impact, for papers by C. Barnas Breakdown of academic impact, for papers by Ádám Nagy Breakdown of academic impact, for papers by A Puech Breakdown of academic impact, for papers by P. J. Perry Breakdown of academic impact, for papers by Meghan M. Grady Breakdown of academic impact, for papers by James F. Pradko Breakdown of academic impact, for papers by Alexander Nies
Rankless by CCL
2026